[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06938542":3,"trial-entities:NCT06938542":143,"trial-summary:NCT06938542":155},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":37,"study_type":51,"primary_purpose":52,"phases":53,"enrollment_info":55,"interventions":58,"primary_outcomes":66,"secondary_outcomes":104,"sex":105,"minimum_age":106,"maximum_age":107,"healthy_volunteers":14,"eligibility_criteria":108,"std_ages":122,"locations":126,"central_contacts":136,"overall_officials":137,"references":141,"see_also_links":142},"NCT06938542","R01HD117137-01","Palliative Care Needs of Children With Rare Diseases and Their Families","ENROLLING_BY_INVITATION","2029-08-02","2026-01","2026-01-28","2025-10-02","Children's National Research Institute","OTHER",true,"The palliative care needs of family caregivers of children with rare diseases and their children are largely unmet, including the need for support to prepare for future medical decision making. This trial will test the FACE-Rare intervention to see if investigators can identify and meet those needs; and if FACE-Rare effects family caregivers' quality of life and child healthcare utilization. Finally, investigators will determine if the intersectionality of child-sex, family-race, Federal poverty level, and social connection influences family quality of life and child health care utilization longitudinally.","Pediatric patients with rare diseases experience high mortality with 30% not living to see their 5th birthday. Families are likely to be asked to make complex medical decisions for their child. Pediatric advance care planning involves preparation and skill development to help make future medical care choices. Children with rare disorders are a heterogeneous group, resulting in their exclusion from research. Available research on families of children with rare diseases lacks scientific rigor. Although desperately needed, there are few empirically validated interventions to address these issues. Investigators propose to close a gap in our knowledge of families' needs for support in a heterogeneous group of children with rare diseases; and to test an advance care planning intervention. The FAmily CEntered (FACE) pediatric advance care planning intervention is adapted to families with children who have rare diseases. Theoretically informed and developed and adapted by the principal investigator and key stakeholders, the proposed intervention will use Respecting Choices Next Steps Pediatric ACP™ for families whose child is unable to participate in health care decision-making. Our consultation with families of children with rare disorders and the National Organization for Rare Disorders (NORD) revealed that basic palliative care needs should be addressed first, prior to an advance care planning intervention. For the study to be able to meet this request, all families randomized to the intervention will first complete the Carer Support Needs Assessment Tool (CSNAT)© adapted by investigators for use in pediatrics. In the CSNAT Approach, facilitators assess caregivers' prioritized palliative care needs and develop Shared Action Plans for increasing informal social support. Thus, investigators propose an innovative 3-session FACE-Rare intervention, integrating two evidence-based approaches. Investigators will evaluate FACE-Rare using a scientifically rigorous intent-to-treat, assessor-blinded, longitudinal, prospective, three-site, randomized controlled trial design. Family\u002Fchild triads (N=160) will be randomized to FACE-Rare (CSNAT Sessions 1 \\& 2 plus Respecting Choices Sessions 3) or an enhanced information Treatment as Usual control group. All families will complete questionnaires at baseline and follow-up at 3-, 6- and 12 months. Investigators will evaluate the effect of FACE-Rare on family quality of life (caregiver appraisal, psychological, spiritual). Investigators will assess the palliative care needs of families at four time points. Investigators will determine the intersectionality of child-sex, family-race, and household income on family caregiver quality of life and child healthcare utilization. Investigators will explore the influence of urban vs. rural setting and religious coping on quality-of-life outcomes. Investigators will use advanced statistical methods informed by statistical advice from rare disease investigators for clinical trials in small populations.",[18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36],"Trisomy 13 Syndrome","Arthrogryposis Congenita Multiplex With Intestinal Atresia","Asparagine Synthetase Deficiency","CHARGE Syndrome","Early Infantile Epileptic Encephalopathy","FOXG1 Syndrome","KBG Syndrome","Noonan Syndrome","Severe Hemophilia A","Short Bowel Syndrome","Beta-Propeller Protein-Associated Neurodegeneration","Brain Injury of Prematurity With Periventricular Leukomalacia","Chromosome 17p13.3 Microdeletion Syndrome","Chromosome 1q43-1q44 Deletion","Cockayne Syndrome","Congenital Diaphragmatic Hernia","End-Stage Renal Disease With Cloacal Anomaly","Mitochondrial Depletion Disorder","Severe Factor VII Deficiency",[38,39,40,41,42,43,44,45,46,47,48,49,50],"pediatrics","palliative care","rare diseases","rare disorders","randomized clinical trial","advance care planning","quality of life","social connection","intervention","spirituality","anxiety","depression","caregiving","INTERVENTIONAL","SUPPORTIVE_CARE",[54],"NA",{"count":56,"type":57},480,"ESTIMATED",[59],{"type":60,"name":61,"description":62,"armGroupLabels":63},"BEHAVIORAL","Family Centered pediatric palliative care for family caregivers of children with rare diseases.","Child with rare disease who is unable to participate in medical decision making\u002Ffamily caregiver\u002Fsupport person triads will be randomized at a 1:1 ratio to one of two study arms, either the 3 session FACE-Rare intervention or the enhanced Treatment as Usual. Assessments will be completed at baseline, 3, 6 and 12 month outcomes.",[64,65],"Enhanced Treatment As Usual (TAU)","FACE-Rare",[67,71,74,78,82,86,89,92,95,98,101],{"measure":68,"description":69,"timeFrame":70},"Family Appraisal of Caregiving for Palliative Care (FACQ-PC)","The FACQ-PC is a 25-item measure consists of four theoretically derived subscales: (i) caregiver strain, (ii) positive caregiving appraisals, (iii) caregiver distress, and (iv) family well-being. Scores are from 5 = strongly agree to 1 = strongly disagree. Investigators will not calculate a Total score. On the subscale scores for positive caregiving appraisals and family well-being, higher scores mean better outcomes, i.e. greater positive caregiving appraisals or family well-being. On the subscale scores for caregiver strain and caregiver distress, higher scores mean worse outcomes, i.e. greater caregiver strain or caregiver distress. The FACQ-PC subscale scores will be computed by taking the mean of the items (score range 1-5). Some items are reverse scored, depending on how the item is phrased, so that higher scores = higher amount of the subscale being measured. So the minimum value for each subscale is 1 and the maximum value for each subscale is 5.","Baseline, 3-, 6-, and 12 month post-intervention",{"measure":72,"description":73,"timeFrame":70},"Functional Assessment of Chronic Illness Therapy-Spirituality-12 Version 4 Expanded (FACIT-Sp-EX)","Assessed construct of spiritual well-being. Two subscales Meaning\u002FPeace (7 items) and Faith (5 items) and Total score (12 items) were calculated. on a 5-point Likert scale from 0=not at all to 5=very much. Some items are reverse scored. See www.facit.org Meaning\u002FPeace subscale score range from minimum value of 0 to maximum value of 32. Higher scores indicate better meaning\u002Fpeace.\n\nFaith subscale score range from 0 minimum value to maximum value of 16. Higher scores indicate better meaning\u002Fpeace.\n\nTotal score range is from 0 minimum value to maximum value of 92. Higher scores indicate better spiritual well-being.",{"measure":75,"description":76,"timeFrame":77},"Advance Care Plan for Child with Rare Disease Located in the Electronic Health Record (EHR).","Documentation of an advance care plan for child with rare disease in the Electronic Health Record and decisional preference - to continue all treatments, to continue all treatments with exceptions noted, to provide comfort care only.","Baseline and 1 year",{"measure":79,"description":80,"timeFrame":81},"Child Healthcare Utilization: initiation of palliative care consultations","Using a standardized data abstraction form to count initiation of palliative care consultations during the study.","Baseline, 3-, 6-, 12-month.",{"measure":83,"description":84,"timeFrame":85},"Generalized Anxiety Disorder-7 (GAD-7)","Quality of life indicator with respect to emotional health-anxiety symptoms. 7 items. Higher scores indicate greater anxiety.","Baseline, 3-, 6-, 12-month",{"measure":87,"description":88,"timeFrame":85},"Patient Health Questionaire-9 (PHQ-9)","Quality of life indicator with respect to emotional health-depressive symptoms. 9 items. Higer scores indicate higher symptoms of depression. A yes response to question 9 (self-harm) will trigger a referral.",{"measure":90,"description":91,"timeFrame":85},"Child Healthcare Utilization: # of days in palliative care before death.","Using a standardized data abstraction form to count # of days in palliative care before death.",{"measure":93,"description":94,"timeFrame":85},"Child Healthcare Utilization: # of hospitalizations during study participation","Using a standardized data abstraction form to count # of days hospitalized during the study.",{"measure":96,"description":97,"timeFrame":85},"Child Healthcare Utilization: # of Emergency Department visits during study participation","Using a standardized data abstraction form to count # of days used Emergency Department during study.",{"measure":99,"description":100,"timeFrame":85},"Child Healthcare Utilization: # of days in the Intensive Care Unit (ICU)","Using a standardized data abstraction form to count # of days was admitted to ICU during the study.",{"measure":102,"description":103,"timeFrame":85},"Child Healthcare Utilization: # of surgeries","Using a standardized data abstraction form to count # of surgeries during the study.",[],"ALL","12 Months","99 Years",{"inclusion":109,"exclusion":119,"raw_text":121},[110,111,112,113,114,115,116,117,115,118,117],"≥1.0 years and \\\u003C18.0 years at enrollment.","Unable to participate in end-of-life care decision-making.","Has a rare disease as operationally defined by NIH's Genetic and Rare Diseases Information Center (GARD).","Not under a Do Not Resuscitate Order or Allow a Natural Death Order.","Not in the Intensive Care Unit.","\\> 18.0 years at enrollment.","Child's family caregiver\u002Flegal guardian.","Not known to be developmentally delayed.","Chosen by family caregiver.",[120],"Family caregiver or support person is actively homicidal, suicidal, or psychotic at the time of enrollment.","Child inclusion criteria:\n\n* ≥1.0 years and \\\u003C18.0 years at enrollment.\n* Unable to participate in end-of-life care decision-making.\n* Has a rare disease as operationally defined by NIH's Genetic and Rare Diseases Information Center (GARD).\n* Not under a Do Not Resuscitate Order or Allow a Natural Death Order.\n* Not in the Intensive Care Unit.\n\nFamily caregiver inclusion criteria:\n\n* \\> 18.0 years at enrollment.\n* Child's family caregiver\u002Flegal guardian.\n* Not known to be developmentally delayed.\n\nSupport person inclusion criteria:\n\n* \\> 18.0 years at enrollment.\n* Chosen by family caregiver.\n* Not known to be developmentally delayed.\n\nExclusion Criteria:\n\n* Family caregiver or support person is actively homicidal, suicidal, or psychotic at the time of enrollment.",[123,124,125],"CHILD","ADULT","OLDER_ADULT",[127],{"facility":128,"city":129,"state":130,"zip":131,"country":132,"geoPoint":133},"Children's National Hospital","Washington D.C.","District of Columbia","20010","United States",{"lat":134,"lon":135},38.89511,-77.03637,[],[138],{"name":139,"affiliation":12,"role":140},"Maureen E Lyon, PhD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":144,"biomarkers":154},[145,19,20,29,21,31,146,32,33,147,148,149,35,150,25,151,152,153,27,18],"15q13.3 microdeletion","Chronic Renal Failure","Developmental and Epileptic Encephalopathy","Factor VII Deficiency","KBG syndrome","Neurodegeneration with Brain Iron Accumulation 5","Rare Disorder","Rett Syndrome, Congenital Variant","Severe hereditary factor VIII deficiency disease",[],{"nct_id":4,"found":156,"summary":157,"prompt_version":157},false,null]